<DOC>
	<DOCNO>NCT01844570</DOCNO>
	<brief_summary>The purpose study determine whether effectiveness levamlodipine maleate ( xuanning ) noninferior amlodipine besylate ( Norvasc ) treatment hypertension Chinese primary hypertension population .</brief_summary>
	<brief_title>Levamlodipine Maleate Amlodipine Besylate Treatment Hypertension : A Comparative Effectiveness Research</brief_title>
	<detailed_description>It multicenter , prospective cohort study large sample size . It evaluate effect incidence cardiovascular cerebrovascular endpoint event blood pressure control hypertensive patient use Levamlodipine Maleate ( Xuanning ) amlodipine besylate ( Norvasc ) .Xuanning group Norvasc group recruit 5000 patient respectively . Each site recruit patient chronological order；patients participate finish two-year follow ( 1,2,3,6,12,18,24 month recruitment ) relevant data record . Baseline data analyze evaluate equilibrium two group ( number option ) . Logistic regression propensity score ( PS ) would use match major indicator effectiveness safety indicator use match method baseline data .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>systolic pressure ≥140mmHg diastolic pressure ≥90mmHg receive antihypertensive drug treatment Patient himself/herself his/her family member already sign informed consent form Patient fit use Levamlodipine Maleate amlodipine besylate Age≥45 patient secondary hypertension patient suffer myocardial infarction stroke within late 3 month patient obvious intelligence、hearing limb 's activity disability Patients severe disease , life expectancy less two year</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>